CTOs on the Move


 
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.janpixbio.com
  • One Broadway, 14th Floor
    Cambridge, MA USA 02142
  • Phone: 617.956.2803

Executives

Name Title Contact Details

Funding

Janpix raised $10M on 10/07/2020

Similar Companies

LifeSpan Biosciences

LifeSpan Biosciences is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio Essence Corp

Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ganeden Biotech

Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pathogen Detection Systems

Pathogen Detection Systems, Inc. is a Thunder Bay, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bonna-Agela Technologies

Bonna-Agela Technologies is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.